T1DM Therapeutics in Major Developed Markets Forecast to Year 2021 3

Type 1 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 - Innovative and
Diversified Pipeline to Drive Market Growth
Despite Patent Expirations
No of Pages – 160
Publishing Date - November 1, 2015
Browse detailed TOC, Tables, Figures, Charts in Type 1 Diabetes Mellitus Therapeutics in
Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market
Growth Despite Patent Expirations at- http://www.absolutereports.com/10070573
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and
Diversified Pipeline to Drive Market Growth Despite Patent Expirations

Summary

Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a
destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune
response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential
glucose metabolism and leads to hyperglycemia (high blood glucose levels). As a result, immediate
and lifelong treatment with exogenous insulin therapy is initiated upon diagnosis of T1DM.
Exogenous insulin has remained the mainstay of T1DM therapy since it was used to treat the first
human patient in 1922.

Consequently, insulin products comprise the vast majority of the T1DM market, which is largely
monopolized by three big pharma players: Eli Lilly, Novo Nordisk and Sanofi. However, insulin
treatment regimens are often inconvenient and are associated with undesirable side effects such as
hypoglycemia (low blood glucose levels) and weight gain. In addition, there is a significant unmet
need for more diversified treatment options including therapies capable of altering the clinical course
of the pathological beta cell destruction and adjuvant therapies capable of improving glycemic
control and reducing insulin requirements.

Scope